NASDAQ Composite Falls 0.70% This Week to 15973.17 — Data Talk
The NASDAQ Composite Index is down 111.94 points or 0.70% this week to 15973.17
--Down for two consecutive weeks
--Down 301.77 points or 1.85% over the last two weeks
--Largest two-week point and percentage decline since the week ending Jan. 5, 2024
--Today it is down 155.36 points or 0.96%
--Largest one-day point and percentage decline since Friday, March 8, 2024
--Down for three consecutive trading days
--Down 292.46 points or 1.80% over the last three trading days
--Largest three-day point and percentage decline since Wednesday, Feb 21, 2024
--Down five of the past six trading days
--Off 1.85% from its record close of 16274.94 hit Friday, March 1, 2024
--Up 43.12% from the Election Day close of 11160.57 on Tuesday, Nov. 3, 2020
--Up 18.70% from the Inauguration Day close of 13457.25 on Wednesday, Jan. 20, 2021
--Lowest closing value since Tuesday, March 5, 2024
--Off 1.85% from its 52-week high of 16274.94 hit Friday, March 1, 2024
--Up 37.34% from its 52-week low of 11630.51 hit Friday, March 17, 2023
--Rose 37.34% from 52 weeks ago
--Off 1.85% from its 2024 closing high of 16274.94 hit Friday, March 1, 2024
--Up 10.08% from its 2024 closing low of 14510.30 hit Thursday, Jan. 4, 2024
--Month-to-date it is down 0.74%
--Year-to-date it is up 961.82 points or 6.41%
Data based on preliminary market closing values
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
March 15, 2024 16:29 ET (20:29 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth